Prophylactic Intrawound Vancomycin Powder in Minimally Invasive Spine Stabilization May Cause an Acute Inflammatory Response

Yuki Hyodo 1, 2, Takeshi Arizono 2, Akihiko Inokuchi 2, Takahiro Hamada 2, Ryuta Imamura 2

1. Department of Orthopaedic Surgery, Kyushu University Hospital, Fukuoka, JPN
2. Department of Orthopaedic Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JPN

Corresponding author: Yuki Hyodo, 3md22050y@s.kyushu-u.ac.jp

Abstract

Introduction

Surgical site infections (SSIs) with methicillin-resistant Staphylococcus aureus are serious complications of spinal instrumentation surgery. Many spine surgeons are concerned that using prophylactic vancomycin powder will lead to certain risks: the development of multidrug-resistant pathogens, anaphylactic reactions, and organ toxicity. Minimally invasive spine stabilization (MIS) is associated with shorter operation times and less blood loss and may therefore require the use of less vancomycin powder, which may reduce these risks. This retrospective comparative study of patients who underwent MIS at a single institution aimed to evaluate the complications (such as allergy, SSIs, and organ toxicity) and the local and serum levels associated with using prophylactic intrawound vancomycin powder compared with IV cefazolin alone.

Methods

Thirty-four patients received intrawound vancomycin powder (1 g) applied during wound closure in minimally invasive posterior lumbar interbody fusion (MIS-PLIF). This group was compared with 133 control patients who did not receive vancomycin. White blood cell counts and C-reactive protein (CRP) levels were measured for both groups on postoperative days (PODs) 1, 3, and 7 and were statistically analyzed. In the vancomycin group, serum vancomycin levels were measured on PODs 1, 3, 7, and 14; drain vancomycin levels and postoperative blood loss were determined on PODs 1 and 2.

Results

The CRP levels on PODs 1 and 3 were significantly higher in the vancomycin group than in the control group (P<0.001, P=0.024). In the vancomycin group, mean drain levels trended downward from 313 μg/mL (POD 1) to 155 μg/mL (POD 2). These levels correlated negatively with drain drainage volume on both days (POD 1: r=−0.48, P=0.015; POD 2: r=−0.47, P=0.019). Mean serum vancomycin levels also trended downward from 2.3 μg/mL (POD 1) to 1.7 μg/mL (POD 14).

Conclusions

Our results unexpectedly demonstrated that the local application of vancomycin powder causes an acute inflammatory response and the long-term detection of low serum vancomycin levels. Less than 1 g of intrawound vancomycin powder may be useful only at high risk of SSI.

Categories: Orthopedics
Keywords: c-reactive protein, acute inflammatory response, surgical site infection, mrsa, vancomycin, instrumentation, lumbar spinal stenosis, minimally invasive posterior lumbar interbody fusion, minimally invasive spine stabilization

Introduction

Surgical site infections (SSIs) are serious complications of spinal instrumentation surgery. In many cases, repeated surgical interventions and long-term antibiotic administration are necessary to control infections, which results in prolonged hospital stays, increased medical costs, reduced patient satisfaction, and poorer functional prognosis [1, 2].

Guidelines in many countries recommend using intravenous (IV) cefazolin to prevent postoperative SSIs in spinal instrumentation surgery. However, the occurrence of difficult SSI cases with methicillin-resistant Staphylococcus aureus (MRSA) infections has been increasing [3]. The penetration of IV vancomycin into the spinal region is poor, and the in vivo vancomycin levels may often be lower than the minimum inhibitory concentration (MIC) of MRSA, which is greater than 1 μg/mL [4-7]. Also, IV vancomycin has been associated with hypotension, anaphylactic reactions, red man syndrome, inhibition of osteoblasts with resultant pseudoarthrosis, renal toxicity, selection and growth of gram-negative organisms, and development of...
vancomycin-resistant organisms in the oropharyngeal, respiratory, and genitourinary tracts [4,5,8]. On the other hand, previous studies showed that adjunctive local application of vancomycin powder reduced the number of postoperative infections in posterior instrumented thoracolumbar spinal fusions with relative safety compared to IV vancomycin [9,10].

Minimally invasive spine stabilization (MIST) is associated with shorter operation times and less blood loss [11]. We believe that less vancomycin powder used in MIST reduces SSI rates and lowers the risk of developing multidrug-resistant pathogens, anaphylactic reactions, and its related complications. The present study aimed to evaluate the complications (such as allergy, SSIs, and organ toxicity) and the local and serum levels associated with using prophylactic intrawound vancomycin powder compared with IV cefazolin alone in MIST.

Materials And Methods

This retrospective comparative cohort study included patients who underwent minimally invasive posterior lumbar interbody fusion (MIS-PLIF) at a single institution between April 2014 and June 2017. A total of 175 patients were initially identified. Eligible to be included in the study were patients who had a lumbar degenerative disease and were treated via minimally invasive procedures, via posterior lumbar interbody arthrodesis, including pedicle screws and interbody cages at one level with at least one year of follow-up. Exclusion criteria included infectious diseases, traumatic pathologies, and neoplastic and multi-level fusion cases. All operations were performed by two out of the three spine surgeons at our institution. There were no differences in surgical technique, implant, and protocol among surgeons. The study protocol was approved by the Institutional Review Board of the authors’ affiliated institution, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers (approval number 236). Patients were informed about the study design and methods and agreed to participate in this study.

All patients received standard antibiotic prophylaxis with 2 g of IV cefazolin within 1 hour of surgical incision followed by IV cefazolin every 8 hours for 48 hours. Patients in the vancomycin group also received 1 g of vancomycin powder directly into the local wounds during closure; approximately 0.5 g of vancomycin powder was applied to the midline incision, and the remaining 0.5 g was applied evenly to the right and left lateral incisions made for the percutaneous pedicle screws.

After surgery, we regularly assessed the patients’ body temperature and the presence or absence of complications (such as allergies, SSIs, and renal toxicity). We measured the number of white blood cells (WBCs) and the levels of C-reactive protein (CRP) on postoperative days (PODs) 1, 3, and 7. For the vancomycin group, we obtained blood samples from wound drains on PODs 1 and 2 to determine postoperative blood loss and vancomycin levels. We also measured serum vancomycin levels on PODs 1, 3, 7, and 14.

All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan, version 1.54), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). We used Mann-Whitney U-tests to compare averages of continuous variables and chi-square tests to compare proportions of categorical variables between groups. We used the Spearman correlation coefficient to determine the relationship between drain drainage volume and vancomycin levels. Power analysis was performed using G*Power ver. 3.1.9.6 (freeware, Franz, Universitat Kiel, Germany). With a power of 80%, 0.05 level of statistical significance, and effect size of 1, the sample size for Mann-Whitney U-tests was calculated to be over 18. The significance threshold was P<0.05.

Results

This study involved 167 patients who met the inclusion criteria. Thirty-four patients who were treated between April 2014 and June 2015 were included in the vancomycin group, and 133 patients who were treated between July 2015 and June 2017 were in the control group. Table 1 shows that the vancomycin group and the control group were statistically similar in terms of demographics.
Both groups had no complications such as allergy, renal toxicity, and SSIs within 30 days. The two groups did not show significant differences in WBC counts and CRP levels on POD 7 (Table 2).

However, on PODs 1 and 3, the CRP levels in vancomycin group patients were significantly increased compared with those in control group patients (P<0.001, P=0.024) although the WBC counts showed no significant difference in the two groups. The time to return to normal body temperature was longer in the vancomycin group than in the control group, but this measure did not reach statistical significance (Table 2).

Mean vancomycin drug levels obtained from surgical drains in the vancomycin group peaked on POD 1 at 313 μg/mL (range 38-909) and dropped to 155 μg/mL (range 50-589) on POD 2. These levels correlated negatively with drain drainage volume (postoperative blood loss) on PODs 1 and 2 (Figure 1).
Significant negative linear correlations were seen between drain drainage volume (postoperative blood loss) and drain vancomycin levels on postoperative days (PODs) 1 and 2.

A: POD 1, r=-0.48, P=0.015. B: POD 2, r=-0.47, P=0.019

Figure 2 shows that mean serum vancomycin levels trended downward from 2.3 μg/mL (POD 1) to 2.1 μg/mL (POD 3) to 1.8 μg/mL (POD 7) to 1.7 μg/mL (POD 14).

Discussion

This study determined that CRP levels in vancomycin group patients on PODs 1 and 3 were significantly increased compared with CRP levels in control group patients, but WBC counts and CRP levels after POD 7 were not significantly different in the two groups. We unexpectedly found that intrawound vancomycin powder caused an acute inflammatory response. In addition, local application of 1 g of vancomycin powder during MIS-PLIF achieved high vancomycin levels in surgical drains on PODs 1 and 2 and low serum vancomycin levels on PODs 1-14. These results suggest that high local vancomycin levels provide local antibiotic concentrations for at least two days postoperatively, and low serum vancomycin levels are unlikely to cause organ toxicity. On the other hand, low serum vancomycin levels had been unexpectedly detected for at least two weeks, and such long-term detection of vancomycin may lead to the development of vancomycin-resistant organisms.
MRSA has been reported as the most common causative microorganism isolated from SSIs [10,12,13]. SSIs after spine surgery are serious complications that negatively affect patient outcomes and greatly increase the morbidity and mortality of patients. Previous studies showed that intrawound application of vancomycin during spine surgery significantly reduced the risks of SSIs and returns to the operating room because of SSIs [9,10,14-19]. In addition, almost all current literature has reported no adverse outcomes attributable to the application of intrawound vancomycin powder [19]. Similarly, in our study, the vancomycin group did not have SSIs within 30 days and complications such as allergy and renal toxicity.

However, several case reports described occurrences of severe hypotension, anaphylactic reactions, and red man syndrome as a result of the local intrawound application of vancomycin powder as used for prophylaxis of infections [20-22]. These are allergic inflammations, and the erythrocyte sedimentation rate (ESR) and CRP are widely used as inflammatory markers. CRP was observed to have a higher diagnostic sensitivity and specificity than ESR in the diagnosis of various inflammatory conditions [23]. Suh et al. reported that on POD 5, the ESR in vancomycin group patients (25.2 ± 19.4 mm/hour) was significantly increased compared with that in control group patients (14.4 ± 14.2 mm/hour, P=0.004) [24]. In our study, the CRP levels on PODs 1 and 5 were significantly higher in the vancomycin group than in the control group. These findings suggest that intrawound vancomycin powder causes an acute inflammatory response including allergic inflammation and is not as safe as once believed.

Local application of vancomycin powder has produced wound drug levels higher than the MIC of MRSA, so infection rates may thereby be reduced. Sweet et al. reported that 2 g of intrawound vancomycin powder resulted in wound concentrations (128-1457 μg/mL) that were nearly 1000-fold higher than the MIC of MRSA in thoracic and lumbar posterior instrumented spinal fusions [10]. Armaghani et al. also reported that the application of 1 g of vancomycin powder in pediatric spinal deformity surgery produced local levels (115-403 μg/mL) that were well above the MICs of common pathogens [25]. As expected, our study here showed that the local concentration of vancomycin (155-313 μg/mL) was higher than the MIC of MRSA when 1 g of intrawound vancomycin powder was applied during MIS-PLIF. In addition, the intrawound application of vancomycin in spine surgery would be unlikely to impair bone healing and affect pseudoarthrosis rates [26-29]. In vitro studies have demonstrated that high local concentrations, up to 10,000 ng/mL, were necessary to inhibit osteogenesis. As demonstrated by our results, the observed local concentrations were well below this concentration.

Vancomycin powder was poorly absorbed from the wound site, so serum vancomycin levels may be much lower than the toxicity threshold (25 μg/mL) [25]. Sweet et al. reported that 80% of patients had undetectable vancomycin blood levels with a minimum sensitivity of 0.6 μg/mL, and only 20% had detectable vancomycin blood levels at low serum concentrations of 1.6 mg/mL on POD 1 [10]. Armaghani et al. reported that serum vancomycin levels trended downward from 2.5 μg/mL (POD 0) to 1.9 μg/mL (POD 1) to 1.1 μg/mL (POD 2) [25]. These low serum vancomycin levels are well below toxic levels (25 μg/mL) and are unlikely to cause organ toxicity. In addition, a meta-analysis indicated that topical vancomycin powder did not increase rates of gram-negative bacterial or polymicrobial spinal infections, as well as rates of infections with gram-positive bacteria, MRSA, and other microorganisms [30]. Our study, however, showed that mean serum vancomycin levels (1.7-2.3 μg/mL) were seen for at least two weeks after MIS-PLIF. This finding suggests that intrawound vancomycin powder was continuously absorbed, little by little, from the wound site. Such long-term detection of vancomycin may lead to some complications and reduced susceptibility or increased tolerance to vancomycin.

Spine surgeons have used empirical doses of 1-2 g of vancomycin powder; therefore, additional pharmacokinetic studies are needed to determine the optimal safe and effective dose for spine surgery [27]. A systematic review showed that patients undergoing MIS consistently had less blood loss than patients undergoing open transfomaminal or posterior lumbar interbody fusion [11]. In our study, local vancomycin levels correlated negatively with postoperative blood loss and were much higher than the MIC of MRSA when 1 g of intrawound vancomycin powder was applied during MIS-PLIF; similar findings were noted for the use of 2 g in thoracic and lumbar posterior instrumented spinal fusions in adults [10] and 1 g in spinal deformity surgery in children [25]. For these reasons, less than 1 g of intrawound vancomycin powder during MIS-PLIF may be sufficiently effective to reduce the risk of SSIs.

Our study has certain limitations. First, we used CRP as a marker of an acute inflammatory response, but it is an imperfect measure of allergic inflammation and does not distinguish differences from other acute inflammatory responses. Second, we included various posterior surgical procedures for spinal conditions with multiple etiologies, and the CRP levels may vary depending on the etiology and operative procedure. Third, this is a retrospective study at a single center. The retrospective data review limited our ability to deduce causal relationships. The number of patients is too small to discuss the complications. Lastly, the possibility of a selection bias cannot be denied; however, we minimized this bias by dividing the two groups according to the time of surgery. A prospective comparative study of a larger number of patients may be necessary to achieve an accurate assessment of vancomycin use.

Conclusions

We unexpectedly found that intrawound vancomycin powder induces an acute inflammatory response and
the long-term detection of low serum vancomycin levels. The inflammatory response may be related to adverse events, including allergic inflammation, and the long-term detection of vancomycin may lead to the development of drug-resistant organisms. On the other hand, we identified no complications, and the local application of less than 1 g of vancomycin powder during MIS-PLIF may reduce the risk of SSIs. These findings suggest that the minimum dose of intrawound vancomycin powder is effective only in patients undergoing MIS-PLIF and at high risk of SSI. Additional studies of vancomycin powder, assess safety immediately after local vancomycin powder application, and evaluate the long-term safety and effectiveness of this drug treatment.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. The Institutional Review Board of the authors’ affiliated institution, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers issued approval 236. This retrospective study was approved by the IRB. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Radcliff KE, Neuner AD, Millhouse PW, et al.: What is new in the diagnosis and prevention of spine surgical site infections. Spine J. 2015, 15:536-47. 10.1016/j.spinee.2014.09.022
2. Smith JS, Shaffrey CI, Sansur CA, et al.: Rates of infection after spine surgery based on 108,419 procedures. A report from the Scoliosis Research Society Morbidity and Mortality Committee. Spine (Phila Pa 1976). 2011, 36:556-65. 10.1097/BRS.0b013e31821ead441
3. Klevens RM, Morrison MA, Nadle J, et al.: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007, 298:1765-71. 10.1001/jama.298.15.1765
4. Gibson MJ, Karpinski MR, Slack RC, Cowlishaw WA, Webb JR: The penetration of antibiotics into the normal intervertebral disc. J Bone Joint Surg Br. 1987, 69:784-6. 10.1302/0301-620X.69B5.6985545
5. Rhoten RL, Murphy MA, Kafus IH, Hahn JF, Washington JA: Antibiotic penetration into cervical discs. Neurosurgery. 1995, 37:418-21. 10.1227/00006123-199509000-00008
6. Soriano A, Marco F, Martinez JA, et al.: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008, 46:195-200. 10.1086/524667
7. Neooh HM, Hori S, Komatsu M, Ogori T, Takeuchi F, Cui L, Hiramatsu K: Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob. 2007, 6:13. 10.1186/1476-0711-6-13
8. Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, Sakulas G: Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother. 2008, 61:85-90. 10.1093/jac/dfm445
9. Chiang HY, Herwaldt LA, Blevins AE, Cho E, Schweizer ML: Effectiveness of local vancomycin powder to decrease surgical site infections: a meta-analysis. Spine J. 2014, 14:397-407. 10.1016/j.spinee.2013.10.012
10. Sweet FA, Rob M, Silva C: Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes. Spine (Phila Pa 1976). 2011, 36:2084-8. 10.1097/BRS.0b013e31821f2eb1
11. Goldstein CL, Phillips FM, Rampersaud YR: Comparative effectiveness and economic evaluations of open versus minimally invasive posterior or transforminal lumbar interbody fusion: a systematic review. Spine (Phila Pa 1976). 2016, 41 Suppl 8:S74-89. 10.1097/BRS.0000000000001462
12. Weinstein MA, McCabe JP, Camnisa FP Jr: Postoperative spinal wound infection: a review of 2,391 consecutive index procedures. J Spinal Disord. 2000, 13:422-6. 10.1097/00002517-200010000-00009
13. O’Neill KR, Smith JG, Abtahi AM, Archer KR, Spengler DM, McGirt MJ, Devin CJ: Reduced surgical site infections in patients undergoing posterior spinal stabilization of traumatic injuries using vancomycin powder. Spine J. 2011, 11:641-6. 10.1016/j.spinee.2011.04.025
14. Khan NR, Thompson CJ, De Guzman M, et al.: A meta-analysis of spinal surgical site infection and vancomycin powder. J Neurosurg Spine. 2014, 21:974-83. 10.3171/2014.8.SPINE14445
15. Molinari RW, Khera OA, Molinari WJ 3rd: Prophylactic intraoperative powdered vancomycin and postoperative deep spinal wound infection: 1,512 consecutive surgical cases over a 6-year period. Eur Spine J. 2012, 21 Suppl 4:S476-82. 10.1007/s00586-011-2104-z
16. Ström RG, Pacione D, Kalhorn SP, Frempong-Boadu AK: Lumbar laminectomy and fusion with routine local application of vancomycin powder: decreased infection rate in instrumental and non-instrumented cases. Clin Neurourol Neurosurg. 2015, 115:1766-9. 10.1016/j.clineuro.2015.04.005
17. Ström RG, Pacione D, Kalhorn SP, Frempong-Boadu AK: Decreased risk of wound infection after posterior cervical fusion with routine local application of vancomycin powder. Spine (Phila Pa 1976). 2015, 38:991-4. 10.1097/BRS.0000000000001219
18. Devin CJ, Chotai S, McGirt MJ, et al.: Intrawound vancomycin decreases the risk of surgical site infection after posterior spine surgery: a multicenter analysis. Spine (Phila Pa 1976). 2018, 43:65-71. 10.1097/BRS.0000000000001571
19. Hey HW, Thiam DW, Koh ZS, et al.: Is intraoperative local vancomycin powder the answer to surgical site infections in spine surgery? Spine (Phila Pa 1976). 2017, 42:267-74. 10.1097/BRS.0000000000001710
20. Mariappan R, Manninen P, Massicotte EM, Bhatia A: Circulatory collapse after topical application of vancomycin powder during spine surgery. J Neurosurg Spine. 2013, 19:581-5. 10.3171/2013.6.SPINE131
21. Nagahama Y, Vanbeek MJ, Greenlee JD: Red man syndrome caused by vancomycin powder. J Clin Neurosci. 2018, 50:149-50. 10.1016/j.jocn.2018.01.044
22. Zhang X, Zhai W, Li M, Guo X: Circulatory collapse during wound closure in spine surgery with an unknown cause: a possible adverse effect of topical application of vancomycin? BMC Anesthesiol. 2021, 21:4. 10.1186/s12871-020-01220-6
23. Lapić I, Padovan A, Bozzato D, Plebani M: Erythrocyte sedimentation rate and C-reactive protein in acute inflammation. Am J Clin Pathol. 2020, 153:14-29. 10.1093/ajcp/aqz142
24. Suh BK, Moon SH, Kim TH, Oh JK, Kwon YS, Park JS, Park MS: Efficacy of antibiotics sprayed into surgical site for prevention of the contamination in the spinal surgery. Asian Spine J. 2015, 9:517-21.
25. Armaghani SJ, Menge TJ, Lovejoy SA, Mencio GA, Martus JE: Safety of topical vancomycin for pediatric spinal deformity: nontoxic serum levels with supratherapeutic drain levels. Spine (Phila Pa 1976). 2014, 39:1683-7. 10.1097/BRS.0000000000000465
26. Bakhsheshian J, Dahiadeh NS, Lam SK, Savage JW, Smith ZA: The use of vancomycin powder in modern spine surgery: systematic review and meta-analysis of the clinical evidence. World Neurosurg. 2015, 83:816-23. 10.1016/j.wneu.2014.12.033
27. Eder C, Schenk S, Trifinopoulos J, Külekci B, Kienzl M, Schildbock S, Ogon M: Does intrawound application of vancomycin influence bone healing in spinal surgery?. Eur Spine J. 2016, 25:1021-8. 10.1007/s00586-015-3945-9
28. Zebala LP, Chuntarapas T, Kelly MP, Talcott M, Greco S, Riew KD: Intrawound vancomycin powder eradicates surgical wound contamination: an in vivo rabbit study. J Bone Joint Surg Am. 2014, 96:46-51. 10.2106/JBJS.L.01257
29. Rathbone CR, Cross JD, Brown KV, Murray CK, Wenke JC: Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J Orthop Res. 2011, 29:1070-4. 10.1002/jor.21543
30. Li S, Rong H, Zhang X, et al.: Meta-analysis of topical vancomycin powder for microbial profile in spinal surgical site infections. Eur Spine J. 2019, 28:2972-80. 10.1007/s00586-019-06143-6